Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Fukuzuyu Pharmaceutical Co., Ltd.
483
•Fukuzuyu Pharmaceutical Co., Ltd.•January 19, 2024

Fukuzuyu Pharmaceutical Co., Ltd. – FDA 483, Jan 19, 2024

Record Details

An FDA inspection conducted from January 15-19, 2024, at an unnamed pharmaceutical manufacturing firm, identified significant deviations from manufacturing quality standards. The Senior Managing Director, Tetsuaki Nishinaga, received a Form FDA 483 outlining four key observations.

Firstly, the quality unit demonstrated inadequate investigation into out-of-specification (OOS) results and critical deviations. Investigations for assay and residual solvent OOS results lacked scientific justification for conclusions and subsequent corrective actions, with batches released despite insufficient root cause analysis and a history of similar issues.

Secondly, shared production equipment was not consistently cleaned and maintained to prevent cross-contamination, particularly between non-hazardous APIs and hazardous substances. Residue was observed in "clean" equipment, and cleaning procedures were not validated for inactivating all hazardous residues. Furthermore, critical standard solutions for cleaning validation failed stability criteria but were still used without proper investigation.

Thirdly, analytical method validation was incomplete, with no documentation for the in-house gas chromatography method used for API release testing.

Finally, control over computerized systems and electronic records in the QC laboratory was deficient. A single individual with oversight of API release had unlimited administrative access to critical software, posing a data integrity risk. Additionally, an integrator system lacked essential data integrity features like forced saving, audit trails, and secure data storage, relying on unsecure floppy disk transfers.

The company is required to thoroughly address these observations to ensure compliance with regulatory standards.

Company
Fukuzuyu Pharmaceutical Co., Ltd.
Inspection date
January 19, 2024
Product type
drugs
Office
Baltimore District Office
Person
  • Nicholas L. Hunt (Senior CSO, Investigator)
View Company Profile

ID · c5d9904b-c85b-43a5-8dfe-d65f1212a327

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Fukuzuyu Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.